Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. by Kosmas, C. et al.
Br. J. Cancer (1991), 64, 494-500
© Macmillan Press
Patients receiving murine monoclonal antibody therapy for malignancy
develop T cells that proliferate in vitro in response to these antibodies as
antigens
C. Kosmas*, A.A. Epenetos & N.S. Courtenay-Luck
Imperial Cancer Research Fund Oncology Group, andDepartment ofClinical Oncology, Royal Postgraduate Medical School,
Hammersmith Hospital, London W12 OHS, UK.
Summary Peripheral blood mononuclear cells (PBMCs) were obtained from patients receiving radioactive
murine monoclonal antibody (MAb) therapy for malignant epithelial tumours, as well as normal controls, and
were tested for the ability ofT cells to proliferate in vitro in the presence of the MAb administered for therapy
(HMFGI), and another isotypically matched antibody of irrelevant specificity (11.4.1).
We studied 13 patients who had one (ten patients) or two (three patients) courses of MAB treatment, 11 age
matched patients with the same histologic types of tumours, that had not received MAbs, and four normal
controls. There was a consistent dose dependent in vitro T cell proliferation in 11 of the 13 patients after MAb
therapy. This was not observed in the pre-therapy group of patients or normal controls, where the T cell
proliferative responses remained baseline. The mean stimulation index (S.I.) in the post-therapy group was
significantly higher than that of the pre-therapy patients and that of normal controls. When the in vitro T cell
proliferative responses of these patients were measured in the presence of HMGF1 MAb (IgGI) and an
isotypically identical, but idiotypically unrelated 11.4.1 MAb (IgGI), there was no statistically significant
difference in the mean S.I. For HMFGI vs 11.4.1 for the whole group of treated patients. When patients were
separated into those who received one and those who received two MAb treatments, a significant increase in
the mean S.I. was observed in the presence of HMFGI, in the group of patients receiving two treatment
courses, suggesting the generation of T cells with specificity for the idiotypic component of the administered
murine immunoglobulin.
In order to further characterise these in vitro cellular responses we incubated PBMCs with and without an
optimal concentration of the MAb (100-300jig ml-'), as defined by the proliferation assay, and compared the
differences in cell subpopulations. A significant increase in the percentage of cells expressing interleukin-2
receptors (IL-2R) was observed after MAb stimulation. The percentage of CD4+ lymphocytes and the
CD4/CD8 ratio increased in all the cases studied, after MAb stimulation, where the percentages of B cells and
NK cells remained relatively constant at less than 2-3% of the total population.
We therefore conclude that murine MAbs administered to patients with cancer can lead to the generation of
T cells which can recognise these MAbs as antigens when presented appropriately in vitro. The main
proliferating population appears to be T helper CD4+ lymphocytes which following stimulation can release
interleukin-2 leading to the expression of high levels of IL-2R.
Murine monoclonal antibodies (MAbs) raised against tumour-
associated antigens have been used in diagnostic (Mach et al.,
1981; Epenetos et al., 1982; Oldham et al., 1984; Siccardi et
al., 1989) and therapeutic trials (Dillman et al., 1983; Carras-
quillo et al., 1984; Epenetos et al., 1987; Stewart et al., 1990).
A major limitation of murine MAbs is the development of
human anti-murine immunoglobuilin antibody (HAMA) re-
sponses (Schroff et al., 1985; Courtenay-Luck et al., 1986). It
has been shown that this response contains increased levels of
IgM as well as IgG antibodies. Furthermore, after repeated
MAb treatment many patients develop anti-idiotypic anti-
bodies (anti-id' or Ab2) (Koprowski et al., 1984; Chatenoud
et al., 1986; Traub et al., 1988). Ab2 could mimic the original
tumour-associated antigen, thus providing an 'internal image',
which can itself act as antigen, leading to the generation of
anti-anti-idiotypic antibodies (anti-id2 or Ab3) with binding
specificities similar to the administered murine MAb (Courte-
nay-Luck et al., 1988). The generation and maintenance of
such an 'idiotypic network' is thought to be important in
immune regulation, as originally postulated by Jerne (Jerne,
1974).
The humoral aspects of the human anti-mouse response
have been studied in detail. What is poorly understood, is the
contribution of the T cells in the generation and intregration
of idiotypic networks. As previously described, when an
individual is immunised with a recall antigen, such as tetanus
toxoid or adenovirus, he/she will develop memory T cells
able to proliferate in vitro in the presence of antigen, indicat-
ing successful immunisation. The secondary humoral immune
response is predominantly IgG and is mediated through T
and B cell interactions. The same mechanism could operate
in the development of secondary humoral responses to
murine immunoglobulins. In order to investigate this, we
undertook a study to determine whether patients receiving
therapeutic doses of murine MAbs, develop T cells able to
respond in vitro to mitogenic signals elicited by these MAbs
when appropriately presented as antigens. In addition we
studied T cell subpopulations involved in this response in
order to address the underlying mechanism.
Patients, materials and methods
Patients andantibody protocols
Histological confirmation of diagnosis and written informed
consent from patients were obtained prior to administration
of radiolabelled MAbs. Twelve patients participating in this
study had stage III or IV ovarian carcinoma and one patient
(male) had a malignant pleural effusion with adenocarcinoma
cells, from an unknown primary (Table I). Their median age
was 63 years (range: 50-68). Of the 11 patients studied
before any MAb administration, seven had stage III or IV
ovarian carcinoma, one (male) had malignant ascites from awn
adenocarcinoma of unknown primary, and three patients had
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Table I Summary of the data related to the MAb treated group ofpatients
Disease Monoclonal antibody Isotope Category of S.L. (± I s.d.)
Patients andstage and amount injected andradioactivity HAMA response in TCPAa
I Ca Ovary HMFGl:5mg 20mCi 9Y 3 3.84±0.35
Stage III
2 Ca Ovary HMFGl:l5mg 20mCi 9Y 2 2.58±0.33
Stage III
3 Ca Ovary HMFG1:IOmg \ 3 4.97±0.90
Stage III + HMFG2b:5 mgJ 150mCi 'l'I
HMFGI:20 mg 24 mCi 9'Y
4 Ca Ovary HMFGl:15mg 100mCi I'lI 2 1.28±0.12
Stage IV 50 mCi 9Y-colloid
5 Ad.Ca.U.P1 HMFGI:15 mg 60 mCi 3lI 3 4.24±0.53
HMFGI:15 mg 60 mCi '3'I
6 Ca Ovary HMFGl:15mg 100mCi '3'I 3 1.65±0.29
Stage III
7 Ca Ovary HMFG1:15mg 20mCi 'Y 3 6.45±2.23
Stage III HMFG1:15mg 100mCi '3'I
+ AUAld:10mg J
8 Ca Ovary HMFG1:25 mg 20mCi DOTA-90Y 2 25.9± 1.78
Stage III
9 Ca Ovary HMFG1:25 mg 20mCi DOTA-90Y 2 7.58± 1.34
Stage III
10 Ca Ovary HMFGI:25 mg 20mCi DOTA-9Y 2 9.86±0.80
Stage III
11 Ca Ovary HMFGI:25 mg 16mCi DOTA-9Y 2 18.66±2.67
Stage III
12 Ca Ovary HMFGI:25 mg 16mCi DOTA-9Y 1 8.95±0.30
Stage III
13 Ca Ovary HMFGI:25 mg 16 mCi DOTA-90Y 2 14.22± 1.73
Stage III
aTCPA: Tcellproliferation assay, S.I. in thepresence ofHMFGI isshown;bHMFG2: MAbwith similar
tissue distribution to HMFGI but more tumour specific (Burchell et al., 1983); cAd.Ca.U.P: Adenocar-
cinoma of Unknown Primary; dAUAI: MAb reacting with a 35 Kd antigen on a variety of epithelial
neoplasms (Spurr et al., 1986).
stage II or III carcinoma of the breast. Their median age was
61 years (range: 45-69). Four of the above patients were
studied for in vitro T cell proliferation before and after
therapy. Three patients (patients 3, 5, 7; see also Table I) in
the study were treated twice.
Eligible patients had received their last course of cytotoxic
drugs and/or radiotherapy 2 months or longer prior to MAb
therapy. In the non-treated group of patients no cytotoxic
drugs or radiotherapy were given for at least the last 3
months. Patients receiving steroids were not included in the
study.
Monoclonal antibodies and mitogens
The murine MAbs used for in vitro T cell proliferation assays
were:
HMFG1 This is a murine IgGl antibody raised against
human milk fat globule. It recognises a large mucin molecule.
HMFG (Human Milk Fat Globule) normally expressed by
the lactating breast, but also by the majority (>90%) of
ovarian, breast, and other carcinomas (Burchell et al., 1983).
11.4.1 This is a murine IgGl antibody raised against
murine major histocompatibility complex antigen H-2Kk (Oi
et al., 1979).
Mitogens Purified PHA (Phytohaemagglutinin; Wellcome,
UK) was used as a non-specific T cell mitogen in order to
exclude the possibility that the patients' T cell responses are
compromised due to disseminated malignancy and/or pre-
vious cytotoxic therapy.
Isolation ofPBMCs and tissue culture conditions
PBMCs were isoalted from 40-50 ml of heparinised peri-
pheral blood by centrifugation over a Lymphocyte Separa-
tion medium density gradient (Flow Lab, Irvine, UK) at
2,000 r.p.m. for 30 min. Cells recovered from the interface
were washed at 1,500r.p.m. for 10min and at 1,100r.p.m.
for 5 min in RPMI 1640 medium (Gibco, Grand Island,
NY), counted and used in proliferation assays. In some
experiments, T lymphocytes were isolated by means of nega-
tive selection. Adherent cells were obtained after incubation
of 3 x 106 PBMCs ml-' of complete tissue culture medium
(TCM) [RPMI 1640 supplemented with 10% heat-inactivated
foetal calf serum (FCS), 2 mmol L-glutamine, 50 U ml-'
penicillin and 50pgml-' streptomycin] in 90 mm petri dishes
(Nunc, Roskilde, Denmark), at 37°C for 2 h in a humidified
atmosphere of 5% CO2 and 95% air. The non-adherent cells
were then depleted of B cells after incubation with magnetic
beads coated with anti-CD19 MAb (DYNAL, UK), which is
a pan-B cell marker. A magnetic bead to cell ratio of 75:1
was used, and after gentle mixing for 30 min at 4°C twice, the
cells bound to the beads were removed by a magnetic particle
concentrator (MPC, DYNAL, UK). The non-bound cells
were phenotyped using fluorescein conjugated MAbs and
were >95% CD3+ (T cells), <0.5% CD20+ (B cells) and
<3% CD15 + (monocytes) as defined by the MAbs Leu-4,
Leu-16 and Leu-Ml (Becton Dickinson, Mountain View,
CA). Cell viability was >95% as determined by dye ex-
clusion. The adherent population was then recovered by
scraping the dishes with the rubber tips of sterile syringe
plungers.
Proliferation assays
PBMCs were incubated at 105 cells per well (1001sl) of
96-well flat-bottomed microtitre plates (Sterilin, Richmond,
Surrey, UK) in complete TCM by adding increasing concen-
trations of MAbs (10-3-1031fgml-') (HMFG1 and 11.4.1
were tested concurrently) or PHA (0.1-10pgml-'). Control
cultures contained cells in TCM without any MAb or PHA,
in order to determine the background proliferation. In the
experiments where T cells were separated from PBMCs, the
adherent population (monocytes) were irradiated (3,000 rad)
and used as antigen presenting cells at 5 x I04 cells per
microculture well (in 50fsI volume) together with 5 x I04 T496 C. KOSMAS et al.
cells (in 501l). The above cell populations were plated in
100 lA of TCM per well containing titrated amounts of the
murine MAbs (10-3-l031gmlh), in a final volume of
0.2 ml. Control cultures contained only responder cells with
and without MAb, only irradiated adherent cells, or res-
ponders cells (T cells) with irradiated adherent cells without
MAb as antigen.
The cells were kept in culture, at 37°C in a humidified
atmosphere of 5% CO2 for 72 h. In the last 16 h of the total
culture period they were pulsed with 3H-thymidine (0.5pLCi
well) (Amersham International, UK), and harvested onto
glass fibre paper using an automatic cell harvester. The incor-
porated radioactivity was determined using a beta-scintilla-
tion counter. Results were expressed as mean c.p.m. ± 1 s.d.
of triplicate microcultures. The stimulation indices were cal-
culated according to the formula; S.I. = c.p.m. at a given
[MAb]/c.p.m. background.
In vitro stimulation ofPBMCs with MAb and cell surface
marker analysis by immunofluorescence
PBMCs (106cells ml-') from patients receiving MAb therapy
and patients in the non-treated group were cultured in vitro
in TCM with or without 100jig ml-' of MAbs as in the in
vitro T cell proliferation assays. The overall culture period
was 7 days. Viable cells were separated by density gradient
centrifugation, washed in PBS/0.2% BSA/0.1% sodium
azide/l% heat-inactivated human AB serum and stained for
30 min at 4°C with saturating amounts of fluorescein isothio-
cyanate (FITC)-conjugated MAbs against: CD3 (Leu-4),
CD2 (Leu-5b), CD4 (Leu-3a), CD8 (Leu-2a), for T cells,
CD20 (Leu-16) for B cells, CD16 (Leu- lla) for NK cells,
CD25 (Tac; low affinity IL-2R) for activated T cells, and
isotype control antibodies (all from Becton-Dickinson,
Mountain View, CA). For dual colour analysis cells were
stained with phycoerythrin (PE)-conjugated anti-CD4, anti-
CD8 antibodies and FITC-anti-CD25. After three washes the
cells were resuspended in PBS and samples were analysed by
an EPICS V cell sorter (Coulter Electronic, Hialeah, FL).
Enzyme-Linked Immunosorbent Assay (ELISA) for Human
Anti-Murine Antibody (HAMA) response
HAMA was determined by an ELISA as previously des-
cribed (Courtenay-Luck et al., 1986). HAMA responses were
subdivided in three categories: Category 1 is a response not
higher than pre-existing HAMA levels; Category 2 moderate
and Category 3 strong response with a prozone phenomenon.
Statistical analysis
The T cell proliferative responses of PBMCs obtained from
patients before MAb therapy, normal individuals, and
patients who had received MAb therapy were compared, and
results expressed as the mean maximal S.I. for each group,
using the two-tailed Student's t-test. In addition T cell pro-
liferation in the presence of the administered, HMFG1 MAb,
was compared with that of the isotype control MAb 11.4.1,
both in terms of c.p.m. and S.I., by the two tailed t-test. P
values of less than 0.05 were considered significant. Data are
given as the mean c.p.m. or S.I. ± 1 s.d.. Treated patients
were considered to be positive for in vitro T cell proliferation
in response to the MAb, if their S.I. was greater than the
mean S.I. of the untreated group of patients by 3 s.d.
Results
Tcellproliferation assays by 3H thymidine incorporation
Eleven out of 13 patients receiving murine MAb therapy
demonstrated an elevated T cell proliferation after in vitro
stimulation with the MAb (HMFGI and 11.4.1) in a dose
dependent manner. The maximum proliferation was observed
at concentrations of murine antibody (100-1,000figml')
(Figures 1 and 2). None of the age matched patients with the
same type of malignancy (ovarian carcinoma) or other
cancers (three patients with breast carcinoma, and one with
peritoneal carcinomatosis from adenocarcinoma of unknown
primary) as well as normal individuals, demonstrated a dose
dependent proliferation. The in vitro proliferative responses
of the post-therapy group shown considerable variability
from patient to patient and for the same patient when
studied at different time intervals after therapeutic antibody
administration. Significant in vitro responses could be observ-
ed as early as 2-4 weeks and as late as 12 months after
treatment.
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Figure 1 In vitro proliferation of a patient's T lymphocytes; a,
before (0), and after (0) MAb therapy, and b, post second
therapy comparison of the T cell proliferation in the presence of
HMFG1 (0) (MAb administered for the therapy) and 11.4.1
(0), an isotype control MAb.
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Figure 2 In vitro proliferation of a patient's T lymphocytes, who
has never received MAb therapy in the presence of HMFG1 (0)
and 11.4.1 (-), compared in the same experiment with the
proliferative response of a patient's T cells in the presence of
HMFGI (0) and 11.4.1 (0), 4 weeks after HMFG1 MAb
therapy.
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Proliferation in vitro ofunfractionated vs T cell enriched
PBMCs
As mentioned in Methods, in some experiments the T cells
were separated from the whole PBMCs population by nega-
tive selection, in order to exclude the possibility that the
MAb, in vitro, might stimulate other populations such as B
lymphocytes or monocytes. Three post-therapy patients and
three pre-therapy control patients were studied in parallel.
There was no difference in the ability of the MAb to elicit a
dose dependent proliferation when T cells plus irradiated
monocytes (as feeders) or unfractionated PBMCs, were used,
in all the three patients studied. Again the pre-therapy res-
ponses remained baseline whether T cells were separated or
not. The background proliferation was estimated from cul-
tures were T cells and irradiated monocytes were not pulsed
with MAb. In addition, T cells alone or irradiated monocytes
alone were tested for their ability to proliferate in the pre-
sence of increasing concentrations of MAb. No proliferation
above the background was observed (data not shown). The
results of a representative case studied before and after MAb
therapy are shown in Figure 3.
Comparison ofthe Stimulation Indices (S.L) between the
groups
Details of patients' histologic diagnosis, stage of the disease,
amounts of radiolabelled MAb in mgs and radioactivity
injected (in mCI of 13'I or 9Y), HAMA responses and S.I. of
the in vitro T cell proliferation assay are shown in Table I.
The mean S.I. of the group of MAb treated patients after
in vitro stimulation with HMFG1 MAb was 8.47 ± 6.97
(n = 13, range: 1.28 to 25.9) which was significantly higher
than the mean S.I. of the pre-therapy group, which was
1.09 ± 0.19 (n = 11, range: 0.90 to 1.57), P<0.005, and the
mean S.I. of the normal control group, which was 1.12 ±
0.18 (n = 4, range: 0.93 to 1.36), P<0.005. There was no
difference between the mean S.I. of the pre-therapy group of
patients and the normal control group.
When T cells from patients receiving MAb therapy were
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tested for their ability to elicit an in vitro proliferative res-
ponse in the presence of the administered MAb (HMFG1;
IgGI) or an isotype control MAb (11.4.1, IgGI), studied in
the same experiment, the mean S.I. for HMFG1 was 8.47 +
6.97 and not statistically higher than the mean S.I. for 11.4.1
which was 6.44 ± 4.78, when the whole group of treated
patients were examined. When patients were grouped into
those treated once, and those treated twice, the following
results were found. For the patients who received one MAb
therapeutic course the mean S.I. for HMFG1 was 11.29 +
7.53 (n = 8), which did not differ significantly from the mean
S.I. for 11.4.1, which was 7.87 ± 4.90 (n = 8). The lympho-
cytes of eight out of ten patients treated once were studied
for proliferation with 11.4.1 MAb. The S.I. of the two
patients studied only with HMFG1 were not included in the
comparative analysis, because they would obviously inbal-
ance the comparison. For those patients treated twice the
mean S.I. for HMFG1 was 5.22 ± 0.91 vs 2.64 ± 0.34 (n = 3)
and the difference was statistically significant, P<0.01. In
addition these patients demonstrated a significantly higher
proliferation in the presence of HMFG1 MAb than 11.4.1
MAb at all the concentrations of MAb in vitro about OILgg
ml-' (P<0.05 by paired t-test). At least three experiments
were performed in each case with high reproducibility of the
results. Results from a representative experiment are shown
(Figure 4).
Immunophenotype analysis oflymphocyte subpopulations after
in vitro stimulation with the MAb as antigen
When the PBMCs obtained from patients who received MAb
therapy, were tested after in vitro stimulation with MAb we
found a significant increase in the number of cells expressing
IL-2R as compared with cells growing in parallel cultures
without MAb. The mean percentage of IL-2R expression in
unstimulated cells was 7.95 ± 2.30% (range: 5-11.4%). After
in vitro MAb stimulation this was 55.10 ± 18.55% (range:
34-80.5%) (P<0.005) in four patients who received MAb
therapy (Table II). When cells from untreated patients were
tested in vitro with or without MAb, there was no change in
the number of cells expressing IL-2R, indicating the absence
of stimulation by the MAb when presented as antigen.
We then estimated the CD4/CD8 ratio after in vitro MAb
stimulation. This showed a consistent increase in the ratio in
stimulated cultures; mean CD4/CD8 = 10.45 ± 3.7 (range:
6.3-15.3), when compared to unstimulated cultures from the
same patient; mean CD4/CD8 = 5.7 ± 0.8 (range: 4.7-6.55),
P<0.025 (Table II). Again there was no change in the
CD4/CD8 ratio when lymphocytes from untreated patients
were cultured in the presence or absence of MAb in the
culture medium (data not shown). When T cells after in vitro
activation were phenotyped with anti-CD4 or anti-CD8-PE
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Figure 3 In vitro T cell proliferative responses: a, of unfrac-
tionated PBMCs from a patient before MAb treatment, and from
another patient after HMFG1 MAb treatment, and b, of frac-
tionated T cells (separated as described in Materials and
methods) obtained from the same patients, described above, in
the presence of HMFGI (before 0, and after 0 therapy) and
11.4.1 (after * therapy).
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Figure 4 In vitro T cell proliferation, as defined by the S.I., for
the three patients (Patients 5, 3, and 7; see also Table I) studied
after two administrations of HMFGI MAb, in the presence of
HMFGI and 11.4.1, at three different in vitro MAb concentra-
tions (10, 100, and 1,000jigml-').
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labelled antibodies and anti-IL-2R-FITC antibody, we
always found that the cells expressing IL-2R were within the
CD4 population. Results of a representative experiment are
shown in Figure 5.
The percentage of B cells, defined by the anti-CD20 (pan-B
cell) MAb, as well as NK cells, defined by the anti-CD16
MAb, did not change significantly in the stimulated vs the
unstimulated PBMCs cultures with the MAb which patients
received for therapy (Table II). In contrast the percentage of
CD2 + lymphocytes demonstrated a slight but consistent
increase in the MAb stimulated lymphocyte cultures obtained
from patients after MAb treatment; mean CD2 percentage =
93.3 ± 2.2 (range: 91.5-96.4), as compared to the unstimu-
lated population; mean CD2 percentage = 78.6 ± 1.92 (range:
76.6-81.2), associated with a significant change in the distri-
bution of the relative number of cells as a function of the
fluorescence intensity. This is consistent with the expression
of an additional epitope of CD2 after T cell activation (data
not shown).
Table II Surface marker analysis of lymphocytes after in vitro
activation with MAb as antigen ( + MAb), and non-activated lympho-
cytes with MAb (- MAb), obtained from four patients after MAb
therapy
% ofpositive cells CD4/CD8
Patients IL-2R CD2 CD20 CD16 ratio
8 -MAb 11.4 - 1.1 - 4.70
+MAb 80.5 - 1.7 - 6.30
9 -MAb 5 78 0.7 1.6 6.50
+MAb 34 91.5 1 1.9 12.80
11 -MAb 7.3 76.6 1.3 1.8 5.20
+MAb 41.2 92 1.5 2.2 7.40
13 -MAb 6.2 81.2 1.7 2.6 6.55
+MAb 64.8 96.4 2 3.2 15.30
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Figure 5 Double fluorescence analysis of T cells with: anti-CD4
a, or anti-CD8-PE b, and anti-IL-2R-FITC after in vitro stimula-
tion with the MAb as antigen, in a patient who received MAb
therapy. CD4 + /IL-2R + cells shown in a (right upper panel),
and CD8 + /IL-2 + cells shown in b (right upper panel).
HAMA results andcorrelation with post-therapy S.L
Twelve out of the 13 treated patients developed a measurable
HAMA response. Our ELISA results showed that five
patients developed strong HAMA responses (Category 3),
seven patients developed Category 2 responses, and one
patient had an undetectable serum HAMA response, after
MAb therapy. All patients who were treated twice (three
patients) developed a Category 3 response. Of the 11 patients
who demonstrated significant increase in T cell proliferation
in response to the MAb in vitro, as defined by the S.I. (S.I.
after treatment> mean S.I. of untreated group + 3 s.d.), four
had developed Category 3, six Category 2, and one Category
1 HAMA responses. Of the two patients negative for T cell
proliferation one developed Category 3 and the other Cate-
gory 2 HAMA response. Within the non-treated group of
patients three of them had increased HAMA serum response
before any MAb therapy which was predominantly IgM.
None of them demonstrated elevated T cell proliferation in
response to the MAb in vitro. One of them entered in the
MAb therapy protocol developed increased HAMA levels
after treatment with a marked prozone effect, as well as a
significant T cell proliferative response in vitro in the presence
of murine MAb.
Discussion
The data presented in this study indicate that T cells obtain-
ed from patients receiving murine MAb therapy for malig-
nant disease are able to proliferate in vitro in the presence of
the MAb as antigen, whereas T cells from age and disease
matched patients as well as normal controls that have never
received murine immunoglobulins do not demonstrate any in
vitro proliferative responses. Therefore MAbs can act as
specific mitogens for T cells in vitro, in conventional pro-
liferation assays, like other known recall antigens such as
tetanus toxoid, purified protein derivative of tuberculin
(PPD) or influenza virus (Morimoto et al., 1985; Smith et al.,
1986). Interpretation of these results suggests that MAb ther-
apy leads to the formation of specific T cell memory in vivo,
and these T cells are able to proliferate in vitro to the MAb.
It is known from previous studies that in vivo activation of
T cells by a recal antigen leads to the acquisition of the
UCHL1 and loss of the CD45R marker. The application of
limiting dilution analysis enabled the investigators to charac-
terise that CD4 + /UCHL1 + T cell subpopulation as the
helper/inducer population (Merkenschlager et al., 1988).
In order to examine the specificity of the observed pro-
liferative response we tested in parallel, the ability of T cells
to proliferate in the presence of an isotypically identical
murine MAb, but with different specificity than that of the
administered MAb. We did not observe any significant differ-
ence in proliferation for the whole group of treated patients
as well as when the group of these treated once was con-
sidered, suggesting that determinants within the constant
region of the murine antibodies, which are common for both
HMFG1 and 11.4.1, are recognised by the majority of pro-
liferating T cells. A similar observation was made when the
humoral responses against murine MAb were studied after
the first MAb treatment. When the group of the three
patients treated twice with HMFG1 was analysed, there was
a significant difference in T cell proliferation in favour of
HMFG1 MAb, suggesting the expansion of T cells recog-
nised restricted determinants on that antibody, i.e. idiotypic
and/or allotypic determinants. Although this finding is based
only on three patients, it is in accordance with previous
findings of our group and other investigators showing the
generation of detecable anti-idiotypic (Ab2) humoral immune
responses after two or more therapeutic MAb administra-
tions. It is known that individuals showing pre-existing
HAMA serum responses have increased levels of circulating
rheumatoid factors which are predominantly of the IgM
subclass and react with the Fc portion of both mouse and
human immunoglobulin (Courtenay-Luck et al., 1987).
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Therefore these patients have B cells able to bind murine
immunoglobulins. It has already been described that B cells
can effectively present exogenous antigens to T cells via an
MHC class II dependent mechanism (Lanzavecchia, 1985).
According to these findings, B cells from peripheral blood of
patients with pre-existing HAMA, before any MAb therapy,
are expected to process and present in vitro the murine MAb
to T cells. In our study there were three patients with
elevated pre-therapy HAMA. The in vitro T cell proliferative
responses to the MAb remained baseline in all these patients
before therapy indicating that although there may be presen-
tation of the murine antibody to T cells in vitro, there are
unable to be primed and proliferate when they have never
encountered that antigen in vivo and therefore generate a
'memory', MAb specific T cell population. An alternative
explanation could well be that the frequency of the antibody
specific B cell population is very low in the peripheral blood
and therefore ineffective for adequate presentation.
Saeki (Saeki et al., 1989) recently described a murine T cell
clone that recognises idiotopes on an Ab2 MAb in the con-
text of MHC class II molecules, and that this clone could
induce B cells to proliferate and produce antibodies specific
for the tumour-associated antigen, which is expressed on a
murine lymphoma tumour (L1210/GZL). In addition they
have demonstrated that this T cell clone responds by pro-
liferation to the heavy chain of the Ab2 MAb, much more
efficiently than either to the intact MAb or monomeric Fab
fragments of that antibody, and the proliferation is resistant
to chloroquine inhibition (Saeki et al., 1990). Whether we can
generate T cell clones with specificity for the tumour-associ-
ated antigen, from patients developing anti-idiotypic anti-
bodies, is at present being studied.
In the present work the results from patients receiving
radiolabelled MAb for therapy, but not for imaging are
presented. We have also tested for in vitro T cell prolifera-
tion, lymphocytes from four patients receiving radiolabelled
MAb for imaging purposes. In these cases the dose of the
MAb is no more than 500fig and no significant T cell
proliferation was observed in any of these patients' PBMCs
(unpublished observations). Although this finding is prelim-
inary, it appears that the in vivo MAb dose may be important
in terms of T cell recognition.
In one study (Lanzavechhia et al., 1988) it was shown that
three patients, after therapeutic MAb administration, deve-
loped T cells specific for murine immunoglobulins, and by
raising T cell clones it was found that some of these
(CD4 + ) had the ability to recognise, and in some instances
kill target cells that had bound and processed the murine
MAb via a class II restricted mechanism. The antigen pre-
senting cells (APC) in that study were cloned autologous
EBV-immortalised B lymphocytes. The aim of that study was
to generate MAb specific T cell clones and the results obtain-
ed suggest that murine MAb therapy can elicit a specific
cytotoxic CD4 + T cell response which is able to destroy the
tumour cells targeted by an anti-tumour MAb.
We subsequently studied the expression of IL-2R after in
vitro incubation of PBMCs with MAb at a concentration
showing significant stimulation in the 3 day proliferation
assays. There was a marked increase in the IL-2R expressing
cells after in vitro MAb stimulation, where unstimulated
PBMCs from the same patient demonstrated very low levels
of IL-2R. When the same experiment was done with PBMCs
from the group of patients that were not treated with MAb,
there was no upregulation in IL-2R expression. This is also
in accordance with the data from the proliferation assays,
indicating that the tumour-associated antibody used in our
study (HMFG1), is not mitogenic for T cells in a non-specific
manner, such as anti-CD3 antibodies, which can activate T
cells by signalling through the CD3 molecule; associated with
the T cell receptor, overcoming the need for antigen specific
recognition by the T cells. The levels of B cells and NK cells
remained very low and relatively constant before and after in
vitro MAb stimulation. This indicates that mainly T cells
were activated, and after they had recognised the MAb as
antigen in vitro, secreted IL-2 and upregulated the IL-2R
expression in an autocrine way, as defined by the anti-Tac
antibody. This antibody has specificity for the low affinity
subunit of the receptor for IL-2, but it is recognised that
both low and high affinity IL-2 receptor subunits are needed
for T cell activation by IL-2 (Robb et al., 1984). This finding
in association with the increased percentage of CD4 +
lymphocytes as well as the CD4/CD8 ratio after MAb stimu-
lation is consistent with the activation of the T helper/inducer
population and the generation of a delayed type-like hyper-
sensitivity response (Saltini et al., 1989). Another pathway of
antigen specific T cell activation is the CD2 surface antigen,
which binds the LFA-3 molecule on the antigen presenting
cell, and this is essential to allow any specific recognition of
the antigen-MHC complex by the T cell receptor (Hunig et
al., 1987). Our finding ofmarginal, but statistically significant
increase in CD2 expression and more importantly the change
in pattern of CD2 expression after in vitro stimulation of T
cells (bimodal; data not shown), obtained from MAb treated
patients, is in accordance with the above known mechanisms
of T cell activation (Sanders et al., 1988).
From the in vitro system applied in our study it is not
possible to define the existence of CD8 + cytotoxic T
lymphocytes that may recognise the MAb processed and
presented by a target cell, either a tumour cell or a peripheral
blood monocyte or an EBV- immortalised B cell. CD8 + T
cells need exogenous IL-2 together with the antigen in order
to proliferate in vitro while endogenously produced IL-2 by T
helper cells is inadequate to support their growth. Murine
MAbs are recognised in this case as exogenous antigens and
the mechanisms of their processing and presentation is more
likely to involve class II restricted recognition by CD4 + T
cells. Therefore in the future, experiments of T cell cloning
and limited dilution analysis are needed to identify cytotoxic
T lymphocytes with specificity to the MAb as antigen.
This study showed that murine MAbs, when administered
to patients with malignancy, are able to act as recall antigens
and be recognised by T cells in a specific manner. It is
therefore possible that when used either unconjugated or as
carriers of radioactive isotopes, cytotoxic drugs, and toxins,
murine MAbs can act themselves as antigens, activate T cells,
and probably focus the host's immune response, leading to
the destruction of the tumour cells they have targeted.
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